We report a case of a 67-year-old woman who underwent an aortic valve replacement with a 23-mm Trifecta prosthesis (St. Jude Medical, St. Paul, MN, USA). We implanted Perceval S (LenoNova, London, UK) after resecting the degenerated leaflets three years later after the first operation. This strategy enabled us to reduce the ischemic time and hence simplify the surgical procedure in addition to providing excellent postoperative hemodynamics. < The Perceval sutureless valve implantation in Trifecta ring is a feasible alternative to transcatheter aortic valve implantation in specific situations.>.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834950 | PMC |
http://dx.doi.org/10.1016/j.jccase.2019.07.008 | DOI Listing |
Multimed Man Cardiothorac Surg
October 2024
Department of Cardiovascular Surgery, Chiba-Nishi General Hospital, Chiba, Japan.
Findings in the present case underscore the potential of sutureless aortic valve utilization in patients with prior prosthetic root replacement, thereby obviating the need for high-risk procedures such as replacing a prosthetic root or reimplanting a coronary artery. A 75-year-old male who had undergone a Bio-Bentall operation with a bioprosthetic Trifecta valve for aortic regurgitation and annuloaortic ectasia eight years prior presented with symptoms of heart failure, notably dyspnoea, attributed to prosthetic valve dysfunction. Although a transcatheter aortic valve implant is often recommended, it was deemed unsuitable in this case due to a history of type B aortic dissection.
View Article and Find Full Text PDFInnovations (Phila)
October 2024
Department of Cardiothoracic Surgery, Jessa Hospital, Hasselt, Belgium.
JACC Cardiovasc Interv
July 2023
Centre for Cardiovascular Innovation, St. Paul's and Vancouver General Hospital, Vancouver, Canada; Cardiovascular Translational Laboratory, Providence Research and Centre for Heart Lung Innovation, Vancouver, Canada; Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address:
Background: There are limited data on the effect of bioprosthetic valve remodeling (BVR) on transcatheter heart valve (THV) expansion and function following valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) in a nonfracturable surgical heart valve (SHV).
Objectives: This study sought to assess the impact of BVR of nonfracturable SHVs on THVs after VIV implantation.
Methods: VIV TAVR was performed using 23-mm SAPIEN3 (S3, Edwards Lifesciences) or 23/26-mm Evolut Pro (Medtronic) THVs implanted in 21/23-mm Trifecta (Abbott Structural Heart) and 21/23-mm Hancock (Medtronic) SHVs with BVR performed with a noncompliant TRUE balloon (Bard Peripheral Vascular Inc).
Catheter Cardiovasc Interv
June 2020
Department of Pediatric Cardiology and Pediatric Intensive Care, Ludwig Maximilians University of Munich, Munich, Germany.
A percutaneous pulmonary valve-in-valve (PPVIV) implantation in small surgical tissue valves may be limited due to the valve's initial diameter. Fracturing of the valve's integrity by high-pressure balloons may enhance the diameter and facilitate subsequent PPVIV with a large valve. To the best of our knowledge, the Trifecta® valve seemed not to be accessible for fracturing.
View Article and Find Full Text PDFJ Cardiol Cases
November 2019
Heart Centre, Zentralklinik Bad Berka, Bad Berka, Germany.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!